{
    "clinical_study": {
        "@rank": "144444", 
        "acronym": "VALID I", 
        "arm_group": [
            {
                "arm_group_label": "valacyclovir 500 mg tablet", 
                "arm_group_type": "Active Comparator", 
                "description": "once daily on day 1 (group A) or on day 8 (group B)"
            }, 
            {
                "arm_group_label": "valacyclovir oral solution 50 mg/ml", 
                "arm_group_type": "Experimental", 
                "description": "10 ml (500 mg) once daily on day 1 (group B) or on day 8 (group A)"
            }
        ], 
        "brief_summary": {
            "textblock": "A new paediatric formulation (oral liquid) has been developed for flexible and accurate\n      dosing of valacyclovir in children. To establish the bioavailability of this new\n      formulation, healthy volunteers will be exposed to the new formulation and to valacyclovir\n      tablets. The concentration of valacyclovir in their blood after exposure to the oral liquid\n      will be measured and compared to the tablet."
        }, 
        "brief_title": "Bioequivalence Study in Healthy Volunteers of a New Paediatric Formulation of Valacyclovir Used for Prophylaxis and Treatment of VZV and HSV Infections in Children, Phase I (VALID I)", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Varicalle Zoster Virus Infection", 
            "Herpes Simplex Virus Infection"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Herpes Simplex", 
                "Herpes Zoster", 
                "Virus Diseases"
            ]
        }, 
        "detailed_description": {
            "textblock": "Bioequivalence of the new valcyclovir formulation will be tested according to the EMA\n      guideline for bioequivalence."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject is at least 18 and not older than 55 years of age at screening.\n\n          -  Subject does not smoke more than 10 cigarettes, 2 cigars, or 2 pipes per day for at\n             least 3 months prior to the first dosing\n\n          -  Subject has a Quetelet Index (Body Mass Index) of 18 to 30 kg/m2, extremes included.\n\n          -  Subject has signed the Informed Consent Form prior to screening evaluations.\n\n          -  Subject is in good age-appropriate health condition as established by medical\n             history, physical examination, electrocardiography, results of biochemistry,\n             haematology and urinalysis testing within 4 weeks prior to the first dose. Results of\n             biochemistry, haematology and urinalysis testing should be within the laboratory's\n             reference ranges (see Appendix A). If laboratory results are not within the reference\n             ranges, the subject is included on condition that the investigator judges that the\n             deviations are not clinically relevant. This should be clearly recorded.\n\n          -  Subject has a normal blood pressure and pulse rate, according to the investigator's\n             judgement.\n\n          -  Female subject is either not of childbearing potential, defined as postmenopausal for\n             at least 1 year or is of childbearing potential with adequate contraception (e.g.\n             hysterectomy, bilateral tubal ligation, (nonhormonal) intrauterine device, total\n             abstinence, double barrier methods, vasectomized partner).\n\n        Exclusion Criteria:\n\n          -  Documented history of sensitivity/idiosyncrasy to medicinal products or excipients.\n\n          -  Positive HIV, hepatitis B or C test.\n\n          -  Therapy with any drug (for two weeks preceding dosing), except for acetaminophen.\n\n          -  Relevant history or presence of pulmonary disorders (especially COPD), cardiovascular\n             disorders, neurological disorders (especially seizures and migraine),\n             gastro-intestinal disorders, renal and hepatic disorders, hormonal disorders\n             (especially diabetes mellitus), coagulation disorders.\n\n          -  Relevant history or current condition that might interfere with drug absorption,\n             distribution, metabolism or excretion.\n\n          -  History of or current abuse of drugs, alcohol or solvents.\n\n          -  Inability to understand the nature and extent of the trial and the procedures\n             required.\n\n          -  Participation in a drug trial within 60 days prior to the first dose.\n\n          -  Donation of blood within 60 days prior to the first dose.\n\n          -  Febrile illness within 3 days before the first dose.\n\n          -  Pregnant female (as confirmed by an HCG test performed less than 4 weeks before the\n             first dose) or breast-feeding female."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "16", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 17, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01689285", 
            "org_study_id": "UMCN-AKF 11.04"
        }, 
        "intervention": [
            {
                "arm_group_label": "valacyclovir 500 mg tablet", 
                "description": "16 healthy adult volunteers (18-55 yr) will be exposed to one tablet", 
                "intervention_name": "valacyclovir 500 mg tablet", 
                "intervention_type": "Drug", 
                "other_name": "Zelitrex"
            }, 
            {
                "arm_group_label": "valacyclovir oral solution 50 mg/ml", 
                "description": "16 healthy adult volunteers (18-55 yr) will be exposed to 10 ml once", 
                "intervention_name": "valacyclovir oral solution 50 mg/ml", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Valacyclovir", 
                "Acyclovir"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "bioequivalence", 
            "pharmacokinetics", 
            "valacyclovir", 
            "peadiatric formulation"
        ], 
        "lastchanged_date": "August 28, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Nijmegen", 
                    "country": "Netherlands"
                }, 
                "name": "Radboud University Nijmegen Medical Centre"
            }
        }, 
        "location_countries": {
            "country": "Netherlands"
        }, 
        "number_of_arms": "2", 
        "official_title": "Bioequivalence Study in Healthy Volunteers of a New Paediatric Formulation of Valacyclovir (VALID I)", 
        "overall_official": {
            "affiliation": "Radboud University", 
            "last_name": "Bas Schouwenberg, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Suspended", 
        "oversight_info": {
            "authority": "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "bioequivalence will be determined by comparing AUC0-inf, Cmax and tmax of both formulations in healthy adult volunteers.", 
            "measure": "Geometric Mean Ratios and 90% confidence intervals of pharmacokinetic parameters of acyclovir taken as valacyclovir tablet or oral solution", 
            "safety_issue": "No", 
            "time_frame": "up to 8 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01689285"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "healthy volunteers will be interviewed for adverse events, laboratory safety assessments will be performed.", 
            "measure": "Determine the safety profile of a single dose of valacyclovir oral solution", 
            "safety_issue": "Yes", 
            "time_frame": "day 1 and 8"
        }, 
        "source": "Radboud University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Radboud University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "August 2013", 
        "why_stopped": "oral liquid was not available"
    }
}